51
|
Vickman RE, Faget DV, Beachy P, Beebe D, Bhowmick NA, Cukierman E, Deng WM, Granneman JG, Hildesheim J, Kalluri R, Lau KS, Lengyel E, Lundeberg J, Moscat J, Nelson PS, Pietras K, Politi K, Puré E, Scherz-Shouval R, Sherman MH, Tuveson D, Weeraratna AT, White RM, Wong MH, Woodhouse EC, Zheng Y, Hayward SW, Stewart SA. Deconstructing tumor heterogeneity: the stromal perspective. Oncotarget 2020; 11:3621-3632. [PMID: 33088423 PMCID: PMC7546755 DOI: 10.18632/oncotarget.27736] [Citation(s) in RCA: 26] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2020] [Accepted: 08/24/2020] [Indexed: 12/14/2022] Open
Abstract
Significant advances have been made towards understanding the role of immune cell-tumor interplay in either suppressing or promoting tumor growth, progression, and recurrence, however, the roles of additional stromal elements, cell types and/or cell states remain ill-defined. The overarching goal of this NCI-sponsored workshop was to highlight and integrate the critical functions of non-immune stromal components in regulating tumor heterogeneity and its impact on tumor initiation, progression, and resistance to therapy. The workshop explored the opposing roles of tumor supportive versus suppressive stroma and how cellular composition and function may be altered during disease progression. It also highlighted microenvironment-centered mechanisms dictating indolence or aggressiveness of early lesions and how spatial geography impacts stromal attributes and function. The prognostic and therapeutic implications as well as potential vulnerabilities within the heterogeneous tumor microenvironment were also discussed. These broad topics were included in this workshop as an effort to identify current challenges and knowledge gaps in the field.
Collapse
Affiliation(s)
- Renee E Vickman
- Department of Surgery, NorthShore University HealthSystem, Evanston, IL, USA.,These authors contributed equally to this work
| | - Douglas V Faget
- Department of Cell Biology and Physiology, Washington University in St. Louis, St. Louis, MO, USA.,These authors contributed equally to this work
| | - Philip Beachy
- Department of Developmental Biology, Stanford University School of Medicine, Stanford, CA, USA
| | - David Beebe
- Department of Biomedical Engineering, University of Wisconsin - Madison, Madison, WI, USA
| | - Neil A Bhowmick
- Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA
| | - Edna Cukierman
- Department of Cancer Biology, Marvin and Concetta Greenberg Pancreatic Cancer Institute, Fox Chase Cancer Center, Temple Health, Philadelphia, PA, USA
| | - Wu-Min Deng
- Department of Biochemistry and Molecular Biology, Tulane University School of Medicine, New Orleans, LA, USA
| | - James G Granneman
- Department of Molecular Medicine and Genetics, Wayne State University, Detroit, MI, USA
| | | | - Raghu Kalluri
- Department of Cancer Biology, MD Anderson Cancer Center, Houston, TX, USA
| | - Ken S Lau
- Department of Cell and Developmental Biology, Vanderbilt University School of Medicine, Nashville, TN, USA
| | - Ernst Lengyel
- Department of Obstetrics and Gynecology, University of Chicago, Chicago, IL, USA
| | - Joakim Lundeberg
- SciLifeLab, Department of Gene Technology, KTH Royal Institute of Technology, Stockholm, Sweden
| | - Jorge Moscat
- Weill Cornell Medicine, Rockefeller University Campus, New York, NY, USA
| | - Peter S Nelson
- Department of Medicine, University of Washington, Seattle, WA, USA
| | - Kristian Pietras
- Department of Laboratory Medicine, Lund University, Lund, Sweden
| | - Katerina Politi
- Department of Pathology, Yale University School of Medicine, New Haven, CT, USA
| | - Ellen Puré
- Department of Biomedical Sciences, University of Pennsylvania, Philidelphia, PA, USA
| | - Ruth Scherz-Shouval
- Department of Biomolecular Sciences, The Weizmann Institute of Science, Rehovot, Israel
| | - Mara H Sherman
- Department of Cell, Developmental and Cancer Biology, Oregon Health and Science University, Portland, OR, USA
| | - David Tuveson
- Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA
| | - Ashani T Weeraratna
- Sidney Kimmel Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD, USA
| | - Richard M White
- Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, USA
| | - Melissa H Wong
- Department of Cell, Developmental and Cancer Biology, Oregon Health and Science University, Portland, OR, USA
| | | | - Ying Zheng
- Department of Bioengineering, University of Washington, Seattle, WA, USA
| | - Simon W Hayward
- Department of Surgery, NorthShore University HealthSystem, Evanston, IL, USA.,Workshop co-chairs
| | - Sheila A Stewart
- Department of Cell Biology and Physiology, Washington University in St. Louis, St. Louis, MO, USA.,Workshop co-chairs
| |
Collapse
|
52
|
Stuani L, Sarry JE. Microenvironmental Aspartate Preserves Leukemic Cells from Therapy-Induced Metabolic Collapse. Cell Metab 2020; 32:321-323. [PMID: 32877685 DOI: 10.1016/j.cmet.2020.08.008] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
Metabolic dialogue between tumors and their microenvironment emerges as a key regulator of chemoresistance, the major barrier for the treatment of several cancers. In this issue of Cell Metabolism, van Gastel et al. decipher the pivotal role of stromal glutamine-derived aspartate to sustain pyrimidine biosynthesis in chemoresistant acute myeloid leukemia (AML) and thus state it as a target for anti-cancer therapy.
Collapse
Affiliation(s)
- Lucille Stuani
- Cancer Research Center of Toulouse, Inserm-U1037, CNRS-ERL6422, F-31024 Toulouse, France; Université de Toulouse, F-31300 Toulouse, France
| | - Jean-Emmanuel Sarry
- Cancer Research Center of Toulouse, Inserm-U1037, CNRS-ERL6422, F-31024 Toulouse, France; Université de Toulouse, F-31300 Toulouse, France.
| |
Collapse
|
53
|
Abstract
Lipid droplets have a unique structure among organelles consisting of a dense hydrophobic core of neutral lipids surrounded by a single layer of phospholipids decorated with various proteins. Often labeled merely as passive fat storage repositories, they in fact have a remarkably dynamic life cycle. Being formed within the endoplasmic reticulum membrane, lipid droplets rapidly grow, shrink, traverse the cytosol, and engage in contacts with other organelles to exchange proteins and lipids. Their lipid and protein composition changes dynamically in response to cellular states and nutrient availability. Remarkably, their biogenesis is induced when cells experience various forms of nutrient, energy, and redox imbalances, including lipid excess and complete nutrient deprivation. Cancer cells are continuously exposed to nutrient and oxygen fluctuations and have the capacity to switch between alternative nutrient acquisition and metabolic pathways in order to strive even during severe stress. Their supply of lipids is ensured by a series of nutrient uptake and scavenging mechanisms, upregulation of de novo lipid synthesis, repurposing of their structural lipids via enzymatic remodeling, or lipid recycling through autophagy. Importantly, most of these pathways of lipid acquisition converge at lipid droplets, which combine different lipid fluxes and control their usage based on specific cellular needs. It is thus not surprising that lipid droplet breakdown is an elaborately regulated process that occurs via a complex interplay of neutral lipases and autophagic degradation. Cancer cells employ lipid droplets to ensure energy production and redox balance, modulate autophagy, drive membrane synthesis, and control its composition, thereby minimizing stress and fostering tumor progression. As regulators of (poly)unsaturated fatty acid trafficking, lipid droplets are also emerging as modulators of lipid peroxidation and sensitivity to ferroptosis. Clearly, dysregulated lipid droplet turnover may also be detrimental to cancer cells, which should provide potential therapeutic opportunities in the future. In this review, we explore how lipid droplets consolidate lipid acquisition and trafficking pathways in order to match lipid supply with the requirements for cancer cell survival, growth, and metastasis.
Collapse
|